The effect of quetiapine in psychotic Parkinsonian patients with and without dementia: An open-labeled study utilizing a structured interview

Journal of Neurology

Volumn 253, Issue 2, 2006, Pages 171-175

  Prohorov, Tatiana ^a   Klein, Colin ^a   Miniovitz, Alla ^a   Dobronevsky, Eugenia ^a   Rabey, Jose Martin ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

BPRS; CGIS; Dementia; Parkinson's disease; Psychosis; Quetiapine

Indexed keywords

CARBIDOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DONEPEZIL; LEVODOPA; QUETIAPINE; RIVASTIGMINE;

ADULT; AGED; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; FEMALE; HAMILTON SCALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; SOMNOLENCE;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; DEMENTIA; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PSYCHOSES, SUBSTANCE-INDUCED; TREATMENT OUTCOME;

EID: 32844465773     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-0943-4     Document Type: Article

References (38)

1. Aarsland D, Larsen JP, Cummings JL, Laake K (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson's disease: a community-based study. Arch Neurol 56:595-601
2. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E (1999) Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 14:866-874
3. Aarsland D, Larsen JP, Tandberg E, Laake K (2000) Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 48:938-942
4. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P (2001) Risk of dementia in Parkinson's disease. A community-based, prospective study. Neurology 56:730-736
5. de Smet Y, Ruberg M, Serdaru M, Dubois B, Lhermitte F, Agid Y (1982) Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry 45:1161-1164
6. Dubois B, Pillon B Cognitive deficits in Parkinson's disease (1997) J Neurol 244:2-8
7. Fernandez HH (2000) Quetiapine for l-dopa induced psychosis in PD. Neurology 55:899
8. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M (1999) Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 14:484-487
9. Fernandez HH, Lannon MC, Friedman JH, Abbott BP (2000) Clozapine replacement by quetiapine for the treatment of drug induced psychosis in Parkinson's disease. Mov Disord 15:579-586
10. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH (2003) Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 18:510-514
11. Friedman JH (2003) Atypical antipsychotics: mechanisms of action. Can J Psychiatry 48:62-64
12. Ford B, Lynch T, Greene P (1994) Risperidone in Parkinson's disease. Comment. Lancet 344:681
13. Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43:2227-2229
14. Goetz CG, Vogel C, Tanner CM, Stebbins GT (1998) Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 51:811-814
15. Jimenez-Jimenez FJ, Tallon-Barranco A, Orti-Pareja M, Zurdo M, Porta J, Molina JA (1998) Olanzepine can worsen parkinsonism. Neurology 50:1183-1184
16. Juncos JL, Roberts VJ, Evatt ML, Jewart RD, Wood CD, Potter LS, Jou HC, Yeung PP (2004) Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 19:29-35
17. Klein C, Gordon J, Pollak L, Rabey JM (2003) Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuropharmacol 26:8-11
18. Levy G, Schupf N, Tang MX, Cote LJ, Louis ED, Mejia H, Stern Y, Marder K (2002) Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 51:722-729
19. Mancini F, Tassorelli C, Martignoni E, Moglia A, Nappi G, Cristina S, Pacchetti C (2004) Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson's disease. Clin Neuropharmacol 27:33-37
20. Marder K, Tang MX, Cote L, Stern Y, Mayeux R (1995) The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 52:695-701
21. McKeith IG, Burn DJ (2000) Spectrum of Parkinson's disease, Parkinson's dementia and Lewy body dementia. In: DeKosky ST (ed) Neurological clinics: dementia. Vol 18. WB Saunders, Philadelphia, pp 865-883
22. Menza MM, Palermo B, Mark M (1999) Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease. Ann Clin Psychiatry 11:141-144
23. Molho ES, Factor SA (1999) Worsening of motor features of parkinsonism with olanzepine. Mov Disord 14:1014-1016
24. Ondo WG, Yuong KD, Ringholz G (2003) Quetiapine for drug-induced psychosis in Parkinson's disease: a double-blind, placebo-controlled, parallel trial. Abstract. Mov Disord 18:1083-1084
25. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbairn A, Tomlinson BE, Perry RH (1985) Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 48:413-421
26. Rabey JM, Treves TA, Neufeld MY, Orlov E, Korczyn AD (1995) Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 45:432-434
27. Reddy S, Factor SA, Molho ES, Feustel PJ (2002) The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 17:676-681
28. Richelson E (1996) Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 57(Suppl 11):4-11
29. Rosebush PI, Mazurec MF (1999) Neurological side effects in neuroleptic native patients treated with haloperidol and risperidone. Neurology 52:782-785
30. Rudolf J, Grond M, Neveling M, Heiss WD (1997) Clozapine induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis. J Neural Transm 104:1305-1311
31. Saller CF, Salama AL (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacol (Berl) 112:285-292
32. Targum SD, Abbott JL (2000) Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol 20:54-60
33. The Parkinson's study group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 340:757-763
34. Weiner WJ, Minagar A, Shulman LM (2000) Quetiapine for 1-dopa induced psychosis in PD. Neurology 54:1538
35. Wolters EC (2001) Psychiatric complications in the treatment of Parkinson's disease. Adv Neurol 86:385-393
36. Wolters EC, Francot CMJE (1998) Mental dysfunctions in Parkinson's disease. Parkinsonism Relat Disord 4:107-112
37. Wolters EC, Tuynman-Qua HG (1995) Dopaminometic psychosis: the role of atypical neuroleptics. In: Alberca R, Ochoa JJ (eds) Pautas actuales en al tratamiento medico y quirurgico de la enfermedad de Parkinson. Inter-Congress, Barcelona, pp 57-268
38. Yamada K, Goto S, Ushio Y (2003) GPi pallidotomy for Parkinson's disease with drug-induced psychosis. Parkinsonism Relat Disord 10:35-40